A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis have?
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis has 467 citations in the OpenAlex counts ScholarIQ stores.
When was A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis published?
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis has 2011 year in the ScholarIQ index.
What is the open-access status of A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis?
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis has closed oa status in the ScholarIQ index.
What is the DOI of A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis?
The DOI for A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis is on the source record.
What is the PMID of A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis?
The PMID for A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis is on the source record.
What is the OpenAlex record for A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis?
The OpenAlex for A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis is on the source record.